Equities analysts predict that NewLink Genetics Corp (NASDAQ:NLNK) will report earnings of ($0.27) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for NewLink Genetics’ earnings. NewLink Genetics posted earnings per share of ($0.20) during the same quarter last year, which indicates a negative year over year growth rate of 35%. The firm is scheduled to announce its next earnings results on Thursday, November 7th.
On average, analysts expect that NewLink Genetics will report full-year earnings of ($0.03) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.08) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover NewLink Genetics.
NewLink Genetics (NASDAQ:NLNK) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.02. NewLink Genetics had a negative net margin of 6,587.56% and a negative return on equity of 34.44%. The firm had revenue of $0.15 million for the quarter.
Several equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of NewLink Genetics from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. ValuEngine upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.
A number of institutional investors and hedge funds have recently bought and sold shares of NLNK. Tower Research Capital LLC TRC raised its holdings in NewLink Genetics by 182.9% in the second quarter. Tower Research Capital LLC TRC now owns 20,317 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 13,136 shares during the period. Jane Street Group LLC acquired a new stake in shares of NewLink Genetics during the second quarter worth $178,000. Requisite Capital Management LLC acquired a new stake in shares of NewLink Genetics during the second quarter worth $185,000. Paloma Partners Management Co acquired a new stake in shares of NewLink Genetics during the second quarter worth $191,000. Finally, Worth Venture Partners LLC raised its holdings in shares of NewLink Genetics by 32.9% during the second quarter. Worth Venture Partners LLC now owns 326,507 shares of the biotechnology company’s stock worth $483,000 after acquiring an additional 80,858 shares during the period. Institutional investors own 29.24% of the company’s stock.
NASDAQ NLNK remained flat at $$1.18 during trading hours on Thursday. 1,149 shares of the company traded hands, compared to its average volume of 396,013. The stock has a fifty day moving average of $1.61 and a two-hundred day moving average of $1.64. NewLink Genetics has a fifty-two week low of $1.13 and a fifty-two week high of $2.48. The firm has a market cap of $43.84 million, a price-to-earnings ratio of -0.82 and a beta of 1.15. The company has a quick ratio of 12.77, a current ratio of 12.77 and a debt-to-equity ratio of 0.08.
About NewLink Genetics
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
Featured Article: What are the benefits of investing in REITs?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.